Mednet Logo
HomeRadiation Oncology
Radiation Oncology

Radiation Oncology

Expert insights on radiation treatment planning, techniques, toxicity management, and multimodal cancer care.

Recent Discussions

Would a metal endobronchial stent within the treatment field change your radiation treatment plan for a thoracic malignancy?

1 Answers

Mednet Member
Mednet Member
Radiation Oncology · Cleveland Clinic

No, a stent placement within an airway would not alter either the appropriateness or the planning of radiotherapy for a thoracic tumor. That said, I would discuss the long-term implications of a stent in an irradiated field and would follow the patient closely with pulmonary medicine to discuss the ...

In patients with perihilar cholangiocarcinoma eligible for liver transplant, what is the protocol for neoadjuvant chemo-RT, particularly when brachytherapy is not available?

2
3 Answers

Mednet Member
Mednet Member
Radiation Oncology · University of Cincinnati College of Medicine

There is a lot of variability in neoadjuvant regimens prior to transplant for hilar cholangiocarcinoma as outlined in the survey paper above. Institutional approaches for total dose, fractionation, and target volumes vary considerably. A couple of points to consider and some personal opinions - Phil...

How do you approach management of a patient with intermediate risk prostate cancer treated upfront with HIFU and intermittent ADT who is later found to have rising PSA and biopsy-proven prostate-confined recurrence?

3
3 Answers

Mednet Member
Mednet Member
Radiation Oncology · University of Utah School of Medicine

These are frustrating situations, and ones I am now seeing frequently as focal therapies have gained traction in the United States. The approach, needless to say, is highly individualized. Often, these glands are quite abnormal in MRI appearance, and there is a concern for fibrosis. My approach is h...

Would you ever consider SRS as a salvage option as an alternative to whole brain radiation for secondary CNS lymphoma?

1
2 Answers

Mednet Member
Mednet Member
Radiation Oncology · Duke University Medical Center

The optimal management of secondary CNS lymphoma is not clear. Clinical considerations include the age and performance status of the patient, distribution of disease (CNS only versus systemic and CNS), prior treatment, etc. In most cases, high-dose methotrexate (HD MTX) based regimens are pursued. I...

Do you omit APBI for lobular histology?

2
1 Answers

Mednet Member
Mednet Member
Radiation Oncology · Varian Medical Systems/Allegheny health network

If meets the other criteria, we do offer APBI. GEC estro and NSABP randomized trials did include lobular pathology.

Would you consider adjuvant radiation therapy for a grade 1 meningioma with an elevated Ki67?

1 Answers

Mednet Member
Mednet Member
Radiation Oncology · GammaWest Cancer Services

An answer to this important question requires conjecture as well as additional details. Ki-67 has indeed in some studies been identified as a promising biomarker [Liu et al., PMID 32118704, Tjuatja et al., PMID 36448071, Chen et al., PMID 29624151], however not uniformly so [Jensen et al., PMID 2929...

How would you manage a patient with PSA persistence after RALP demonstrating metastasis in regional lymph nodes without further evidence of disease on bone or CT scans?

1
1 Answers

Mednet Member
Mednet Member
Radiation Oncology · Virginia Commonwealth University Medical Center

First, if possible, I would try to get a PSMA PET/CT. If that is negative, this patient should be started on long-term ADT. In terms of radiation, if they were a candidate for radical prostatectomy, the age/performance status question is probably not a major concern unless their health status has un...

Would you offer salvage radiation for prostate bed recurrence on PSMA PET in a patient with limited bone mets?

3
1 Answers

Mednet Member
Mednet Member
Radiation Oncology

I don’t currently offer salvage post-op RT (PORT) to patients with osseous metastatic disease on PSMA-based PET/CT, which is consistent with the per-protocol treatment strategy on EMPIRE-1 (Jani et al., PMID 33971152). I would, however, be open to offering such a treatment on a clinical trial. An ex...

Is there a role for reirradiation for SCC oral tongue with high-risk features (i.e., PNI, close margins) following surgery?

2
2 Answers

Mednet Member
Mednet Member
Radiation Oncology · Moffitt Cancer Center

Consider in patients with ENE, positive margins, deeply infiltrative tumors (>1 cm), or T4. Avoid if <6 mo from prior RT, ongoing wound healing issues in target, or pre-existing severe toxicity (e.g., ORN, severe fibrosis), though this is conditional.

Are there any bladder constraints for preoperative short course rectal RT?

2
2 Answers

Mednet Member
Mednet Member
Radiation Oncology · Henry Ford Health System

While I appreciate thoughts on constraints by Fields et al., PMID 31673654 (14 patients), or even our paper from Myerson et al., PMID 24606849 (76 patients), I think these are superseded by the higher level of evidence from the RAPIDO study (462 patients w/ SCRT).The RAPIDO study (appendix F, page 8...